Marks DH - Search Results

1

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.

Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE. Kanesa-thasan N, et al. Among authors: marks dh. Vaccine. 2000 Oct 15;19(4-5):483-91. doi: 10.1016/s0264-410x(00)00191-2. Vaccine. 2000. PMID: 11027812 Clinical Trial.

2

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. Van Kampen KR, et al. Vaccine. 2005 Jan 11;23(8):1029-36. doi: 10.1016/j.vaccine.2004.07.043. Vaccine. 2005. PMID: 15620476 Clinical Trial.

3

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE. Sigal LH, et al. N Engl J Med. 1998 Jul 23;339(4):216-22. doi: 10.1056/NEJM199807233390402. N Engl J Med. 1998. PMID: 9673299 Free article. Clinical Trial.

4

Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine.

Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP. Keller D, et al. Among authors: marks dh. JAMA. 1994 Jun 8;271(22):1764-8. JAMA. 1994. PMID: 8196120 Clinical Trial.

5

Cutaneous schistosomiasis: epidemiological and clinical characteristics in returning travelers.

Iriarte C, Marks DH. Iriarte C, et al. Among authors: marks dh. Int J Dermatol. 2023 Mar;62(3):376-386. doi: 10.1111/ijd.16389. Epub 2022 Sep 12. Int J Dermatol. 2023. PMID: 36096120 Review.

6

Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy.

Marks DH, Mansh MD. Marks DH, et al. JAMA Dermatol. 2020 Dec 1;156(12):1380-1381. doi: 10.1001/jamadermatol.2020.4380. JAMA Dermatol. 2020. PMID: 33146681 No abstract available.

7

A Potential Role for IL-4 and IL-13 in an Alopecia Areata-Like Phenotype: A Clinical Perspective.

Marks DH, Senna MM. Marks DH, et al. J Investig Dermatol Symp Proc. 2020 Nov;20(1):S58-S59. doi: 10.1016/j.jisp.2020.04.008. J Investig Dermatol Symp Proc. 2020. PMID: 33099387 Free article.

8

Vaccination Against Human Papillomavirus.

Marks DH, Katz KA. Marks DH, et al. JAMA Dermatol. 2020 Nov 1;156(11):1246-1247. doi: 10.1001/jamadermatol.2020.2927. JAMA Dermatol. 2020. PMID: 32822454

9

Shared medical appointments for female pattern hair loss.

Senna MM, Marks DH, Smith GP. Senna MM, et al. Among authors: marks dh. J Am Acad Dermatol. 2021 Jan;84(1):180-182. doi: 10.1016/j.jaad.2020.04.066. Epub 2020 Apr 20. J Am Acad Dermatol. 2021. PMID: 32325109 No abstract available.

10

Health Insurance Coverage of Permanent Hair Removal in Transgender and Gender-Minority Patients.

Thoreson N, Marks DH, Peebles JK, King DS, Dommasch E. Thoreson N, et al. Among authors: marks dh. JAMA Dermatol. 2020 May 1;156(5):561-565. doi: 10.1001/jamadermatol.2020.0480. JAMA Dermatol. 2020. PMID: 32211825 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page